Studies comparing the efficacy and cost of stem cell mobilization with intermediate-dose CY (ID-CY) and G-CSF against plerixafor and G-CSF, specifically in multiple myeloma (MM) patients treated in the novel therapy era, are not available. Eighty-eight consecutive patients undergoing mobilization with ID-CY (3-4 g/m 2 ) and G-CSF (n ¼ 55) were compared with patients receiving plerixafor and G-CSF (n ¼ 33). Compared with plerixafor, ID-CY use was associated with higher median peak peripheral blood CD34 þ cell count (68 vs 160 cells/mL, Po0.001), and CD34 þ cell yield on day 1 of collection (6.9 Â 10 6 vs 11.7 Â 10 6 cells/kg, Po0.001). Total CD34 þ cell yield was significantly higher in the ID-CY patients (median collection 16.6 Â 10 6 vs 11.6 Â 10 6 cells/kg; Po0.001). ID-CY use was associated with significantly more frequent episodes of febrile neutropenia (16.3% vs 0%; P ¼ 0.02), intravenous antibiotic use (16.3% vs 3%; P ¼ 0.03) and hospitalizations (P ¼ 0.02). The average total cost of mobilization in the plerixafor group was significantly higher compared with the ID-CY group ($28 980 vs $22 504.8; P ¼ 0.001). Our data indicate robust stem cell mobilization in MM patients treated with novel agents, with G-CSF and either ID-CY or plerixafor. When compared with plerixafor, ID-CY-containing mobilization was associated with significantly lower average total mobilization costs.
INTRODUCTION
High-dose therapy and autologous hematopoietic cell transplantation (auto-HCT) is a standard option for younger, transplanteligible multiple myeloma (MM) patients.
1,2 PBSC and PBPC mobilization for auto-HCT is frequently performed by using cytokines, most commonly G-CSF, either alone or in combination with chemotherapy or plerixafor. [3] [4] [5] [6] The best PBPC mobilization method in MM is controversial. However, suboptimal collection outcomes in certain subgroups of MM patients (for example, those with prolonged lenalidomide exposure) mobilized with G-CSF alone are well known. 7, 8 In contrast, chemotherapybased mobilization has been shown to improve PBPC collection yield and reduce mobilization failure rates, 9 with limited retrospective data suggesting that CY may overcome the effects of prior lenalidomide exposure on PBPC mobilization in MM patients. 10 CY doses employed for mobilization in MM have ranged from 1 g/m 2 up to 7 g/m 2 . PBPC mobilization in MM patients treated in the pre-novel therapy era with intermediate-dose CY (ID-CY; 3-4 g/ m 2 ) and G-CSF when compared with low-dose CY (LD-CY; 1-2 g/ m 2 ) and G-CSF was shown to be associated with a higher total CD34 þ cell yield, but at the cost of significantly higher toxicity. 11, 12 We previously compared ID-CY with LD-CY in MM patients treated in the era of novel induction therapies, and reported significantly improved mobilization outcomes and reduced mobilization failure rates in favor of ID-CY and G-CSF, without an unacceptable increase in infectious complications. 13 In MM patients treated with novel inductions, it appears that ID-CY and G-CSF have a favorable risk/benefit ratio and can be considered to be a regimen with an optimal dose intensity for comparison against the efficacy of novel mobilization strategies.
Plerixafor is a small molecule that inhibits chemokine stromal cell-derived factor 1-a from binding to chemokine receptor 4. Despite the promising results of plerixafor and G-CSF for PBPC mobilization in MM, 3 the use of chemotherapy-based mobilization remains common in many transplant centers, driven in part by the costs associated with plerixafor-based strategies. No randomized trials have compared chemomobilization with plerixafor plus G-CSF. Although a few retrospective studies have reported on the relative efficacy of CY-based mobilization against plerixafor, they included patients who received LD-CY, 14 contained patients with non-Hodgkin's lymphoma 14, 15 and likely included MM patients who received conventional inductions. 14, 15 We report here our retrospective data comparing efficacy, toxicity and cost analysis of PBPC mobilization with G-CSF and either ID-CY or plerixafor in MM patients receiving novel induction regimens.
PATIENTS AND METHODS

Patient population
A total of 88 consecutive, adult patients with MM undergoing high-dose therapy and auto-HCT following PBPC mobilization with ID-CY plus G-CSF or plerixafor plus G-CSF were included. All patients underwent a planned, single autograft within 1 year of starting an induction chemotherapy regimen, containing at least one novel agent (thalidomide, lenalidomide or bortezomib) between January 2003 and September 2012. Patients fulfilling these criteria and undergoing mobilization with CY and G-CSF constitute the ID-CY group, whereas patients receiving G-CSF and plerixafor for mobilization formed the plerixafor group. The study was approved by the institutional review board and the protocol review and monitoring committee at each institution.
PBPC mobilization and collection ID-CY was used for PBPC mobilization in Georgia Health Sciences University. CY was administered as an intravenous infusion at a dose of 1.5-2 g/m 2 per day on days 1 and 2 along with MESNA as described previously. 13 All patients received antiemetic prophylaxis with ondansetron 20 mg intravenously 30 min before chemotherapy, and hydration with 1000 mL normal saline before chemotherapy. G-CSF (10 mg/kg/day subcutaneously) was started on day þ 3 and continued until the completion of apheresis. All patients in the ID-CY received antimicrobial prophylaxis with levofloxacin, acyclovir and fluconazole.
Plerixafor and G-CSF for mobilization was used from April 2010 onwards in West Virginia University Hospitals, as described previously. 15 Briefly, patients received G-CSF (10 mg/kg per day subcutaneously) daily for 5 days and plerixafor (0.24 mg/kg subcutaneously) on the evening of day 4, 11 h before the initiation of apheresis the next day. Plerixafor, G-CSF and apheresis were repeated daily for up to 3 additional apheresis sessions. For patients in the ID-CY group, peripheral blood CD34 þ cell count was measured daily when the patient's WBC count recovered to X4000 cells/mL or from day þ 12 onwards (whichever occurred first). When the peripheral blood CD34 þ cell count was X10 cells/mL, apheresis was started.
All collections were performed with a COBE SPECTRA apheresis system (CaridianBCT, Lakewood, CO, USA) by processing three to four blood volumes. It is the institutional policy at both transplant centers to routinely target collection of a sufficient number of CD34 þ cells (that is, a minimum of 5 Â 10 6 CD34 þ cells/kg and a target of X10 Â 10 6 CD34 þ cells/kg) to administer two rounds of high-dose therapy and auto-HCT. Determination of peripheral blood CD34 þ cell count and CD34 þ cell content of the apheresis product was performed at the HLA Laboratory of Georgia Health Sciences University and the Flow Cytometry Laboratory of West Virginia University Hospitals by using International Society of Hematotherapy and Graft Engineering guidelines. 16 The BD FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA, USA) was used for all analyses. The final products were cyropreserved in 10% DMSO using a controlled rate freezer and stored in liquid nitrogen.
Transplantation procedure and supportive care
All patients received uniform conditioning with melphalan 200 mg/m 2 (reduced to 140 mg/m 2 in patients with renal insufficiency) on day À 2, followed by infusion of autologous PBPC on day 0. All patients received post transplant growth factor support (G-CSF 5 mg/kg), fungal, herpes zoster/herpes simplex and bacterial prophylaxis per institutional guidelines. The time of neutrophil engraftment was considered to be the first of three successive days with absolute neutrophil count X0.5 Â 10 9 cells/L after post transplantation nadir. The time of platelet engraftment was considered to be the first of three consecutive days with platelet count 20 Â 10 9 cells/L or higher in the absence of platelet transfusion for preceding 7 days.
Cost determination
Data on costs of PBPC mobilization, apheresis and cryopreservation were assessed as described previously by Shaughnessy et al. 15 Costs were calculated per patient in both groups (including all reimbursable procedures, hospitalizations and costs of all medications during mobilization). A subset analysis was performed to evaluate the cost of mobilization for patients undergoing apheresis for a total of 1, 2, 3 and 4 sessions. The costs related to mobilization and apheresis are shown in Table 1 and are adjusted to reflect 2012 US dollars. Cost of hospitalization during mobilization was estimated from the reimbursement rates of Centers for Medicare and Medicaid Services (CMS) inpatient Prospective Payment System and Diagnosis-Related Groups. Median national CMS reimbursement rates were used to determine the mobilization, apheresis and cryopreservation costs, and are indicated in Table 1 . Medication prices were based on the average sale price for each product. The average sale price was estimated from the average wholesale price by using methods described by Shaughnessy et al. 15 
Statistical analysis
Baseline categorical variables were compared using w 2 , whereas continuous variables were compared by Wilcoxon rank-sum test or a two-sample t-test as appropriate. Successful mobilization was defined as a total of X2 Â 10 6 CD34 þ cells/kg patient body weight in the final product. 'Good mobilizers' were defined as patients yielding X5 Â 10 6 CD34 þ cells/kg in 1-2 days as described previously. 7 To account for differences in the For purposes of calculating medication dosages, a standard height of 5 feet 8 inches and weight of 75 kg were selected based upon data of the average male and female in the United States. The CY dose was calculated to be 6.65 g, based on standard dosing of 3.5 g/m 2 . The 2 h infusion rate of CY was chosen based upon package insert recommendations.
f Cost of hospitalization was estimated from the reimbursement rates of Centers for Medicare and Medicaid Services Inpatient Prospective Payment System and DiagnosisRelated Groups.
CY or plerixafor for PBPC mobilization F Awan et al number of collection days across patients, data were analyzed regarding peak peripheral blood CD34 þ cell count and CD34 þ stem cell collection on day 1 only. All P-values are two sided. Analyses were run using SYSTAT 13 (Systat Software Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
The baseline characteristics of 88 consecutive patients included in this analysis are shown in Table 2 . In all, 55 patients underwent mobilization with ID-CY and G-CSF, whereas 33 patients received plerixafor and G-CSF. The two groups did not differ significantly at baseline; except for a lower mean, HCT comorbidity index and a higher proportion of African-American patients in the ID-CY cohort. More patients in the plerixafor group had bortezomibcontaining inductions (72.7% vs 54.5%), but there was no significant difference in lenalidomide exposure in both groups (48.4% vs 40%; P ¼ 0.43).
Efficacy characteristics
The patients in the ID-CY group started apheresis at a mean of 12.06 days (range 11-14 days) after CY administration, whereas all patients in the plerixafor group started apheresis on day 5 of G-CSF administration. The total CD34 þ cell yield was significantly higher in the ID-CY patients (median collection 16.6 Â 10 6 cells/kg vs 11.6 Â 10 6 cells/kg; Po0.001; Table 3 ). To account for differences in the number of collection days across patients, we compared peak peripheral blood CD34 þ cell count and CD34 þ cell collection on day 1 of apheresis only. Mobilization with ID-CY was associated with significantly higher peak peripheral blood CD34 þ cell counts (median 160 CD34 þ cells/mL vs 68 CD34 þ cells/mL; Po0.001) and day 1 yield of CD34 þ cells (median 11.7 Â 10 6 cells/kg vs 6.9 Â 10 6 cells/kg; Po0.001). As the number of CD34 þ cells collected in the ID-CY group was not available until the next day, hence, despite an average day 1 yield of X10 million CD34 þ cells/kg, the median number of apheresis sessions was two in this group. Unlike the ID-CY patients, the CD34 þ collection yield was available on the same day of collection in the plerixafor group. As detailed in Table 3 , there were no PBPC mobilization failures in either group. There was no significant difference between the two groups for the total number of apheresis sessions performed and in terms of the number of patients collecting at least 2, 5 or 10 million CD34 þ cells/kg, and for the proportion of patients meeting the definition of 'good mobilizers'; however, significantly more patients in the ID-CY group received more than one apheresis session (P ¼ 0.005).
Next, we assessed the efficacy of mobilization in the subgroup of patients who received lenalidomide before transplantation. In all, 16 patients in the plerixafor group and 22 patients in ID-CY group had previously received lenalidomide-based regimens (P ¼ 0.43). There were no mobilization failures in either group. The total median CD34 þ cell yield in lenalidomide-treated patients undergoing ID-CY mobilization was significantly higher than in patients undergoing plerixafor mobilization (16.6 Â 10 6 vs 8.8 Â 10 6 cells/kg, respectively; P ¼ 0.01). The median number of apheresis session in lenalidomide-treated patients, in similar order, was 2 (range 1-4) and 2.5 (1-4; P ¼ 0.29) respectively. Toxicity and supportive care None of the patients in the plerixafor group, but nine (16.3%) patients in the ID-CY group, had febrile neutropenia (P ¼ 0.02; Table 4 ). This was also reflected in the higher use of intravenous antibiotics (16.3% vs 3%; P ¼ 0.03) in the ID-CY group. Hospitalization was required in 20% of the patients in the ID-CY group for a median of 4 days, compared with only one hospitalization in the plerixafor group because of central venous catheter-related complications. Compared with the plerixafor cohort, significantly CY or plerixafor for PBPC mobilization F Awan et al more patients in ID-CY group required packed RBC transfusions (6% vs 34.5%; P ¼ 0.002) and had a trend toward higher frequency of platelet transfusions (6% vs 21.8%; P ¼ 0.07) respectively, between start of chemotherapy and/or growth factor administration for mobilization and completion of PBPC collection. There were no mobilization-related deaths or intensive care unit admissions in either group. Table 5 . There was no significant difference in the average (mean) apheresis-related costs between the ID-CY and plerixafor groups ($9603.7 vs $9273.4, respectively; P ¼ 0.68). The administration of plerixafor was associated with significantly less costs for G-CSF (Po0.0001), blood product administration (P ¼ 0.001) and hospitalization (P ¼ 0.02). However, likely due to significantly higher treatmentspecific costs, the average total mobilization costs in the plerixafor group ($28 980) were significantly higher compared with the ID-CY group ($22 504.8; P ¼ 0.001). In patients requiring only a single day of apheresis, a statistically nonsignificant trend toward lower cost was seen with plerixafor compared with ID-CY ($16 086.1 vs $18 344.3; P ¼ 0.34) as shown in Table 5 . However, the average total cost of mobilization with plerixafor was significantly greater for patients requiring 2, 3 or 4 apheresis days when compared with patients requiring similar number of apheresis sessions in the ID-CY cohort (Table 5) .
Mobilization costs Mobilization costs are summarized in
Engraftment outcomes
All patients proceeded to high-dose therapy with melphalan and auto-HCT. Patients in the ID-CY group were infused a significantly higher median CD34 þ cell dose (12.9 Â 10 6 (range: 2.3-40) cells/ kg vs 5.6 Â 10 6 (range: 3.3-9.5) cells/kg; Po0.001). Median time to neutrophil engraftment was significantly shorter in the ID-CY group (median 10 days, range 8-15 days) compared with the plerixafor group (median 13 days, range 11-22 days; Po0.001). Similarly, median time to platelet engraftment was significantly 11-36 days) ; P ¼ 0.03).
DISCUSSION
In this study we have analyzed PBPC mobilization outcomes following CY-based mobilization against a plerixafor-containing strategy in a uniform cohort of MM patients treated in the era of novel agents, and have made several observations. First, our data suggest that when compared against an optimal CY dose, plerixafor-containing strategy offers no clear benefit in terms of stem cell collection parameters. Second, mobilization with ID-CY, in line with previous data, was associated with a higher incidence of infectious complications, hospitalizations and transfusion requirements. Third, PBPC with plerixafor was associated with higher average total mobilization costs. Although many MM patients with well-controlled disease may be able to successfully mobilize stem cells with cytokine-only strategies, 8 mobilization failure rates in myeloma patients with certain risk factors (prior lenalidomide use, radiotherapy, heavily pretreated disease, advanced age and so on) approach 30-35%. [17] [18] [19] Chemotherapy-based methods may be preferred when immediate control of the underlying disease is required. 15 However, the toxicity and resource utilization with chemotherapybased mobilization strategies are well known. 9, [11] [12] [13] 15, 20 The benefit of adding plerixafor to G-CSF for mobilization in MM was demonstrated in a randomized study. 3 If not for its cost, plerixafor would likely enjoy widespread use for PBPC mobilization because it is effective and relatively safe. 6 No prospective studies have compared chemomobilization with plerixafor plus G-CSF. Although a few retrospective studies have compared CY-based mobilization against plerixafor and G-CSF, they used a range of CY doses, 14, 15 and included histologies in addition to MM. In the present report, we have compared plerixafor-based mobilization against an optimally dosed CY-based strategy in a uniform cohort of novel therapy era MM patients.
In our study, there were no mobilization failures in either group; however, administration of ID-CY provided a significantly higher total CD34 þ cell yield. Shaughnessy et al. 15 in their retrospective study compared CY-based (3-5 g/m 2 ) mobilization against plerixafor. Significantly more patients in their study receiving plerixafor collected more than 5 million CD34 þ cells/kg (94% vs 76%). No such difference was noted in our study. Approximately 40% of patients in the study of Shaughnessy et al. 15 had nonHodgkin's lymphoma, which could be a possible explanation for this difference. It is important to point out that the mobilization kinetics of MM patients receiving plerixafor in our study appears roughly similar to ones available from the prospective study by Dipersio et al. 3 Costa et al. 14 compared LD-CY mobilization against a G-CSF plus just-in-time plerixafor approach, and reported significantly higher rates of mobilization failure with CY-based mobilization. It is probable that the frequency of mobilization failures observed in their study was largely a reflection of CY dose employed. Relatively high rates of mobilization failures in MM patients treated with novel agents following LD-CY have been reported previously. 13 The significantly higher resource utilization in terms of packed RBC and platelet transfusion support and hospitalizations for infectious complications with ID-CY seen in our study has been reported previously. 12, 15, 21 The median time to neutrophil engraftment was significantly longer in the plerixafor group. This could be because of two possible reasons. One, the median infused CD34 þ cell dose in the plerixafor group was significantly lower. Second, post transplant filgrastim started on day þ 5 in the plerixafor group compared with day þ 1 in ID-CY patients.
The higher average mobilization cost of plerixafor group is largely because of the cost of this effective, but expensive, drug. It is possible that a reduction in the cost of plerixafor could make this strategy more cost neutral. In the elegant analysis by Shaughnessy et al. 15 mobilization with plerixafor was found to be cost neutral when compared with CY. Their study used a minimum threshold of 6 million CD34 þ cells/kg, which is close to the 5 million CD34 þ cells/kg cutoff used in our study. There are some possible explanations for this difference. The study by Shaughnessy et al. 15 included both patients with MM and nonHodgkin's lymphoma, whereas our analysis was restricted to MM patients. The rates of hospitalization with CY in the prior study of 58%, compared with 20% in our study, could have led to higher costs of mobilization. Similar to the findings of Shaughnessy et al. 15 plerixafor appeared to be cost neutral in patients finishing mobilization in 1 day; however, this benefit disappeared in patient needing two or more sessions of apheresis. As the median day 1 yield in the plerixafor group in our study was X5 million CD34 þ cells/kg, it is possible that for those transplant centers that target a total CD34 þ cell dose of 5 million CD34 þ cells, plerixafor may represent a cost-neutral strategy. Patients included in our study mostly underwent standard volume apheresis. Several investigators have shown improved CD34 þ collection yields with large-volume apheresis (X20 L of blood processed), but with possibly more profound thrombocytopenia, electrolyte and coagulation abnormalities. 22 Some 22, 23 but not all studies 24 suggest reduced numbers of apheresis sessions to reach target CD34 þ yields with large-volume apheresis compared with standard-volume apheresis. Whether plerixafor-based mobilization would have a better cost profile in patients uniformly undergoing large-volume apheresis is not known and merits further investigation. Like previous studies addressing the cost of plerixafor mobilization, a limitation of this study is that our cost estimates do not necessarily reflect the actual reimbursement and institutional overhead associated with mobilization. Similarly reimbursements vary depending on the patient's insurance provider (Medicaid vs. Medicare vs private insurance carriers). However, instead of estimating our institutional costs, which might not be applicable to other centers in the country, we adopted a previously published methodology 15 to make our analysis relevant to a broader range of transplant programs. The patients in the ID-CY group started apheresis at a mean of 12.06 days after CY administration, whereas all patients in the plerixafor group started apheresis on day 5 of G-CSF administration. For patients traveling long distances to their respective transplant centers, the average 12 days required to initiate mobilization with CY can potentially mean significant out-of-pocket patient expenses (lodging, meals and so on) as well as longer times away from work for both the patients and their caregivers, and merits consideration while deciding the optimal mobilization strategy.
Our data caution against the assumption that plerixafor-based mobilization has efficacy and is cost comparable to traditional chemotherapy-based approaches, at least for the novel therapy era MM patients. Many investigators [25] [26] [27] [28] [29] have shown the feasibility of a just-in-time approach, based on the day 4 CD34 þ cell level, to decide whether plerixafor should be added to an otherwise G-CSF-only mobilization to rescue patients likely to fail or have an inadequate mobilization yield. It is probable that such an approach may have a favorable cost profile; however, no convincing data, compared with an appropriately dosed chemotherapy mobilization, are available.
In conclusion, our data indicate robust mobilization in novel therapy era MM patients with G-CSF and either ID-CY or plerixafor. When compared with plerixafor, ID-CY mobilization was associated with higher but manageable toxicities and lower average total mobilization costs.
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